360 related articles for article (PubMed ID: 22607853)
1. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL
Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
[TBL] [Abstract][Full Text] [Related]
4. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
[TBL] [Abstract][Full Text] [Related]
5. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Cavender MA; Bhatt DL; Stone GW; White HD; Steg PG; Gibson CM; Hamm CW; Price MJ; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; Harrington RA;
Circulation; 2016 Sep; 134(10):723-33. PubMed ID: 27482008
[TBL] [Abstract][Full Text] [Related]
6. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
White HD; Chew DP; Dauerman HL; Mahaffey KW; Gibson CM; Stone GW; Gruberg L; Harrington RA; Bhatt DL
Am Heart J; 2012 Feb; 163(2):182-90.e4. PubMed ID: 22305835
[TBL] [Abstract][Full Text] [Related]
7. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Sawlani NN; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
Circ Cardiovasc Interv; 2017 Jan; 10(1):. PubMed ID: 28039321
[TBL] [Abstract][Full Text] [Related]
8. Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
Abnousi F; Sundaram V; Yong CM; Prats J; Deliargyris EN; Stone GW; Hamm CW; Steg PG; Gibson CM; White HD; Price MJ; Généreux P; Desai M; Yang L; Ding VY; Harrington RA; Bhatt DL; Mahaffey KW
Am Heart J; 2017 Jun; 188():147-155. PubMed ID: 28577670
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
[TBL] [Abstract][Full Text] [Related]
10. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.
Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL;
J Am Coll Cardiol; 2017 Jan; 69(2):176-185. PubMed ID: 28081827
[TBL] [Abstract][Full Text] [Related]
11. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
[TBL] [Abstract][Full Text] [Related]
12. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).
Vaduganathan M; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL;
Am J Cardiol; 2017 Oct; 120(7):1043-1048. PubMed ID: 28802512
[TBL] [Abstract][Full Text] [Related]
13. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL;
Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723
[TBL] [Abstract][Full Text] [Related]
14. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
Généreux P; Stone GW; Harrington RA; Gibson CM; Steg PG; Brener SJ; Angiolillo DJ; Price MJ; Prats J; LaSalle L; Liu T; Todd M; Skerjanec S; Hamm CW; Mahaffey KW; White HD; Bhatt DL;
J Am Coll Cardiol; 2014 Feb; 63(7):619-629. PubMed ID: 24184169
[TBL] [Abstract][Full Text] [Related]
15. Platelet inhibition with cangrelor in patients undergoing PCI.
Harrington RA; Stone GW; McNulty S; White HD; Lincoff AM; Gibson CM; Pollack CV; Montalescot G; Mahaffey KW; Kleiman NS; Goodman SG; Amine M; Angiolillo DJ; Becker RC; Chew DP; French WJ; Leisch F; Parikh KH; Skerjanec S; Bhatt DL
N Engl J Med; 2009 Dec; 361(24):2318-29. PubMed ID: 19915221
[TBL] [Abstract][Full Text] [Related]
16. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
Eisen A; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
Int J Cardiol; 2018 Jan; 250():49-55. PubMed ID: 29030140
[TBL] [Abstract][Full Text] [Related]
17. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
Steg PG; Bhatt DL; Hamm CW; Stone GW; Gibson CM; Mahaffey KW; Leonardi S; Liu T; Skerjanec S; Day JR; Iwaoka RS; Stuckey TD; Gogia HS; Gruberg L; French WJ; White HD; Harrington RA;
Lancet; 2013 Dec; 382(9909):1981-92. PubMed ID: 24011551
[TBL] [Abstract][Full Text] [Related]
18. Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Bhatt DL; Stone GW; Mahaffey KW; Gibson CM; Steg PG; Hamm CW; Price MJ; Leonardi S; Gallup D; Bramucci E; Radke PW; Widimský P; Tousek F; Tauth J; Spriggs D; McLaurin BT; Angiolillo DJ; Généreux P; Liu T; Prats J; Todd M; Skerjanec S; White HD; Harrington RA;
N Engl J Med; 2013 Apr; 368(14):1303-13. PubMed ID: 23473369
[TBL] [Abstract][Full Text] [Related]
19. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
Stone GW; Généreux P; Harrington RA; White HD; Gibson CM; Steg PG; Hamm CW; Mahaffey KW; Price MJ; Prats J; Deliargyris EN; Bhatt DL
Eur Heart J; 2018 Dec; 39(46):4112-4121. PubMed ID: 30203006
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
Angiolillo DJ; Schneider DJ; Bhatt DL; French WJ; Price MJ; Saucedo JF; Shaburishvili T; Huber K; Prats J; Liu T; Harrington RA; Becker RC
J Thromb Thrombolysis; 2012 Jul; 34(1):44-55. PubMed ID: 22569899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
